RT Journal Article
A1 Portuguese, Andrew J.
A1 Fang, Min
A1 Tuazon, Sherilyn A.
A1 Pont, Margot
A1 Qu, Xiaoyu
A1 Shasha, Carolyn
A1 Comstock, Melissa
A1 Lyons, Justina
A1 Cole, Gabriel
A1 Newell, Evan W.
A1 Glynn, Emily
A1 Soma, Lorinda A.
A1 Green, Damian J.
T1 Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma
JF Blood Advances
JO Blood Adv
YR 2023
DO 10.1182/bloodadvances.2023011295
VO 7
IS 23
SP 7235
OP 7238
SN 2473-9529
AB TO THE EDITOR:Anti-CD38 monoclonal antibodies (mAbs) are approved for multiple myeloma (MM) in the first-line and relapsed/refractory settings.1,2 Resistance portends a poor prognosis, yet underlying mechanisms have not been well characterized.3 Despite the generally high CD38 expression on most malignant plasma cells (PCs), variation in the surface level may affect the clinical efficacy of targeted therapy.4-9 Unfortunately, therapeutic anti-CD38 mAbs can interfere with detection and quantification of PC CD38 surface levels by conventional clinical flow cytometry (FC) assays for up to 6 months.10-12 Thus, the prevalence and course of CD38 antigen escape have not been well characterized.
RD 11/15/2025
UL https://doi.org/10.1182/bloodadvances.2023011295